论文部分内容阅读
在最近十年中,治疗哮喘的药物发生了戏剧性的改变。首先,应用纤维支气管镜对支气管进行组织学研究发现,哮喘的病理基础是支气管粘膜炎症,而不仅仅是由于平滑肌痉挛引起;其次,长期有规律地使用β_2-肾上腺素受体兴奋剂已越来越引起临床上的争议,因为临床研究表明β_2-肾上腺素受体兴奋剂不能有效地控制支气管炎症,也不能明显降低哮喘患者的死亡率。因此,目前世界上已有许多国家、地区逐步开始重视抗炎药物在哮喘治疗中的作用。 1 对哮喘的新认识 “哮喘”一词来源于希腊文,表示喘气或气促。
Dramatic changes have taken place in the treatment of asthma in the last decade. First of all, the use of fiberoptic bronchoscopy on the bronchial histological study found that the pathological basis of asthma is the bronchial mucosal inflammation, not just due to smooth muscle spasm; Second, the long-term regular use of β_2-adrenergic receptor agonist has been more The more clinically controversial because clinical studies have shown that β 2 -adrenergic receptor agonists do not effectively control bronchial inflammation and do not significantly reduce mortality in asthmatics. Therefore, many countries and regions in the world have gradually begun to pay attention to the role of anti-inflammatory drugs in the treatment of asthma. 1 New understanding of asthma The word “asthma” comes from the Greek, which means panting or shortness of breath.